The HDAC7 Knockout HT29 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human HT29 colon adenocarcinoma cell line. This pool comprises cells with targeted disruption of the HDAC7 gene, generating a loss-of-function model for studying histone deacetylase 7 function. The polyclonal format provides a heterogeneous knockout population, enabling robust and reproducible experiments without the need for clonal isolation.
HT29 cells are human colon adenocarcinoma epithelial cells widely used as an intestinal epithelial barrier model and in cancer biology research. These cells exhibit epithelial morphology and are well-characterized for studies on colorectal cancer progression, drug screening, and signaling pathway analysis. The HT29 background provides a relevant context for investigating HDAC7??s role in colon cancer biology and epithelial homeostasis.
HDAC7 is a class IIa histone deacetylase that represses gene transcription through deacetylation of histones and non-histone proteins. Its activity is dynamically regulated by phosphorylation-dependent nucleocytoplasmic shuttling, with upstream regulators including protein kinase D (PKD), Ca2?/calmodulin-dependent kinase (CaMK), VEGF, and TGF-??. Upon phosphorylation, HDAC7 binds 14-3-3 proteins and translocates to the cytoplasm, relieving transcriptional repression. Nuclear HDAC7 interacts with transcription factors such as MEF2 and corepressor complexes containing N-CoR, SMRT, and HDAC3, deacetylating histones H3 and H4 to silence target genes. Key downstream effectors influenced by HDAC7-mediated repression include MEF2-dependent genes, p53, Cyclin D1, and Bcl-2, linking HDAC7 to cell proliferation, apoptosis, and angiogenesis.
In HT29 cells, HDAC7 knockout disrupts normal gene repression programs, potentially altering cell cycle progression, apoptotic thresholds, and angiogenic signaling. Given the role of HDAC7 in VEGF signaling and its responsiveness to hypoxia, this knockout model is particularly valuable for dissecting crosstalk between chromatin remodeling and tumor microenvironment cues in colon adenocarcinoma. The loss of HDAC7 may sensitize cells to HDAC inhibitors or other therapeutic agents, providing a platform for drug development and mechanistic studies.
Researchers can employ these HDAC7 knockout polyclonal cells for epigenetic regulation studies, including histone acetylation assays to assess global chromatin changes. They are suitable for cancer cell proliferation assays such as MTT and for apoptosis analysis via flow cytometry. The knockout model enables investigation of VEGF signaling through migration and invasion assays, as well as Western blotting and RT-qPCR to quantify pathway components. Interaction studies using co-immunoprecipitation can map HDAC7-containing complexes. Furthermore, these cells serve as a tool for HDAC inhibitor drug screening and for examining TGF-??-mediated transcriptional responses. For comprehensive support and additional details, please contact Ascent Research.
